Pashtoon M. Kasi, MD, MS

home / authors / pashtoon-m-kasi-md-ms

Articles

HER2+ mCRC: Managing Adverse Events Associated With Antibody Drug Conjugates

Kristen Ciombor, MD, MSCI;Joleen M. Hubbard, MD;Joel R. Hecht, MD;Pashtoon M. Kasi, MD, MS;Kanwal Raghav, MD

February 27th 2023

Comprehensive insight on the adverse event profile of antibody drug conjugate therapy as it compares to other agents in HER2+ metastatic colorectal cancer management.

Trastuzumab Deruxtecan in HER2+ mCRC

Kristen Ciombor, MD, MSCI;Joleen M. Hubbard, MD;Joel R. Hecht, MD;Pashtoon M. Kasi, MD, MS;Kanwal Raghav, MD

February 20th 2023

Centering discussion on clinical trials and experience with trastuzumab deruxtecan, expert oncologists identify its value in the HER2+ treatment landscape.

First-Line Treatment Options for mCRC

Kristen Ciombor, MD, MSCI;Joleen M. Hubbard, MD;Joel R. Hecht, MD;Pashtoon M. Kasi, MD, MS;Kanwal Raghav, MD

February 20th 2023

After a brief overview on first-line treatment options for patients with metastatic colorectal cancer, panelists highlight the role HER2 status plays in the selection of novel therapies.

Challenges With Molecular Testing in Metastatic Colorectal Cancer

Kristen Ciombor, MD, MSCI;Joleen M. Hubbard, MD;Joel R. Hecht, MD;Pashtoon M. Kasi, MD, MS;Kanwal Raghav, MD

February 16th 2023

A comprehensive discussion on the barriers to molecular testing in metastatic colorectal cancer, along with challenges in utilizing these tests in the real-world setting.

Circulating Tumor DNA to Guide Treatment Selection for mCRC

Kristen Ciombor, MD, MSCI;Joleen M. Hubbard, MD;Joel R. Hecht, MD;Pashtoon M. Kasi, MD, MS;Kanwal Raghav, MD

February 16th 2023

Panelists consider the potential role for circulating tumor DNA to inform the selection of therapy for patients with metastatic colorectal cancer.

Role of Tissue Versus Circulating Tumor DNA in Molecular Testing in mCRC

Kristen Ciombor, MD, MSCI;Joleen M. Hubbard, MD;Joel R. Hecht, MD;Pashtoon M. Kasi, MD, MS;Kanwal Raghav, MD

February 9th 2023

Shared insight on the value tissue and circulating tumor DNA respectively provide in molecular testing for patients with metastatic colorectal cancer.